

## DOCTORAL THESIS

### Development of halofuginone, artesunate liposomes and crocetin $\gamma$ -cyclodextrin inclusion complex

Wong, Ka Hong

*Date of Award:*  
2020

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

## ABSTRACT

The water solubility of drug molecules plays an important role in consideration of formulation development to treat a wide range of diseases. In this project, two kinds of drug delivery systems, cyclodextrins and liposomes, were developed for insoluble drug delivery to treat Alzheimer's disease (AD) and colorectal cancer (CRC), respectively.

AD is an irreversible neurodegenerative disorder associated with the accumulation of amyloid-beta (A $\beta$ ) fibrils. Approximately 10% of people aged 65 and above have AD. Crocetin (CRT) is an active compound isolated from the fruits of gardenia (*Gardenia jasminoides* Ellis) and the stigmas of saffron (*Crocus sativus* L.). It has been reported to show various neuroprotective activities. However, poor water solubility and bioavailability are the major obstacles in developing pharmaceutical formulations of CRT. To address the issues, CRT liposomal formulations and CRT-cyclodextrin inclusion complexes were developed and evaluated. CRT-cyclodextrin inclusion complexes significantly increased the water solubility of CRT from the range  $\mu\text{g/mL}$  to  $\text{mg/mL}$ . The CRT- $\gamma$ -cyclodextrin inclusion complex (1:3 molar ratio of CRT/ $\gamma$ -cyclodextrin) was chosen for further studies as it showed the highest encapsulation efficiency ( $94.73 \pm 0.86\%$ ). The formulation had no toxicity to neuronal cells nor AD model cells within the experimental concentration range (0.625 to 100  $\mu\text{M}$  of CRT). It could downregulate the expression of C-terminus fragments and decrease both intracellular and extracellular levels of A $\beta$ , which are hallmarks of AD. It also showed dose-dependent neuroprotective and antioxidant effects against H<sub>2</sub>O<sub>2</sub>-induced cell death. Pharmacokinetics and biodistribution studies showed that this CRT- $\gamma$ -cyclodextrin inclusion complex was suitable for intravenous administration. The

formulation significantly increased the bioavailability of CRT and facilitated CRT crossing the blood-brain barrier to enter the brain.

Similar to AD, CRC is increasingly prevalent with aging populations. Approximately 60% of CRC patients are aged 70 and above. Halofuginone (HF) is an active pharmaceutical ingredient (API) originated from Chinese quinine (*Dichroa febrifuga* Lour.) and artesunate (ART) is a semi-synthetic derivative of artemisinin (ATS) extracted from annual wormwood (*Artemisia annua* L.). Both APIs show anticancer activities by inhibiting the growth of CRC. However, low aqueous stability limits their applications. Liposome formulation with surface functionalization by CPP2 cell-penetrating peptide was developed to deliver HF and ART for targeted CRC therapy. CPP2 is a peptide that can selectively penetrate colon cancer cells. The liposomal drug formulations had uniform particle size (about 100 nm), high encapsulation efficiency (over 80%) and good stability upon 14 days of storage. In cellular uptake study, CPP2-modified liposome showed stronger permeability and selectivity to colon cancer lines without inducing lysosomal degradation. CPP2 surface-modified liposomal drugs demonstrated greater anticancer activities than free form of drugs or conventional liposomal drugs. Combinations of HF and ART formulations notably decreased cancer cell viability as compared to single formulation alone, which indicated that HF and ART formulations exhibited synergistic anticancer effects at specific ratios.

To conclude, the drug delivery systems, cyclodextrins and peptide-modified liposomes, which were developed for AD and CRC treatment, successfully improved the aqueous solubility of insoluble APIs extracted from Chinese medicinal plants.

# TABLE OF CONTENTS

|  |             |
|--|-------------|
| <b>DECLARATION.....</b>  | <b>i</b>    |
| <b>ABSTRACT.....</b>   | <b>ii</b>   |
| <b>ACKNOWLEDGEMENTS.....</b>   | <b>iv</b>   |
| <b>TABLE OF CONTENTS.....</b>  | <b>v</b>    |
| <b>LIST OF TABLES.....</b>   | <b>xii</b>  |
| <b>LIST OF FIGURES.....</b>  | <b>xiii</b> |
| <b>LIST OF ABBREVIATIONS.....</b>                                      | <b>xvi</b>  |
| <b>CHAPTER 1 – Introduction: Background and Literature Review.....</b> | <b>1</b>    |
| 1.1 Importance of water solubility of drugs.....                       | 1           |
| 1.2 Water solubility enhancement technologies.....                     | 2           |
| 1.2.1. Particle size reduction techniques.....                         | 2           |
| 1.2.1.1 Antisolvent precipitation.....                                 | 3           |
| 1.2.1.2 Air jet milling.....   | 4           |
| 1.2.1.3 Ball milling.....  | 4           |
| 1.2.1.4 High-pressure homogenization.....                              | 5           |
| 1.2.2 Solid dispersion.....  | 6           |
| 1.2.3 Chemical modification.....                                       | 7           |
| 1.2.3.1 Salt formation and pH adjustment.....                          | 7           |
| 1.2.4 Cyclodextrin complexation.....                                   | 8           |
| 1.2.4.1 Co-precipitation.....  | 10          |
| 1.2.4.2 Kneading method.....   | 11          |
| 1.2.4.3 Microwave irradiation.....                                     | 11          |

|  |    |
|--|----|
| 1.2.4.4 Drying of inclusion complexes.....                       | 12 |
| 1.2.4.5 Release of guest molecules from inclusion complexes..... | 12 |
| 1.2.5 Liposome encapsulation.....                                | 12 |
| 1.2.5.1 Classification of liposomes.....                         | 14 |
| 1.2.5.2 Functionalized liposomes.....                            | 14 |
| 1.2.5.3 Freeze-dried liposomes.....                              | 15 |
| 1.2.6 Solid lipid nanoparticles.....                             | 15 |
| 1.2.7 Polymeric micelles.....                                    | 16 |
| 1.3 Objectives of the study.....                                 | 18 |

## **CHAPTER 2 – Preparation and Characterization of Crocetin**

|  |           |
|--|-----------|
| <b>Formulations for Alzheimer’s Disease Treatment.....</b>             | <b>20</b> |
| 2.1 Introduction.....  | 20        |
| 2.2 Materials and methods.....   | 25        |
| 2.2.1 Materials.....   | 25        |
| 2.2.2 Experimental procedures.....                                     | 25        |
| 2.2.2.1 UV absorption spectrum of CRT.....                             | 25        |
| 2.2.2.2 Solubility of CRT.....   | 26        |
| 2.2.2.3 Preparation of CRT formulations.....                           | 26        |
| 2.2.2.3.1 Preparation of CRT liposomes.....                            | 26        |
| 2.2.2.3.2 Characterization of CRT liposomes.....                       | 27        |
| 2.2.2.3.3 Preparation of CRT-CD inclusion complexes.....               | 28        |
| 2.2.2.3.4 Characterization of CRT- $\gamma$ -CD inclusion complex..... | 29        |
| 2.2.2.4 Statistical analysis.....                                      | 29        |

|   |           |
|---|-----------|
| 2.3 Results.....  | 30        |
| 2.3.1 UV spectrum of CRT.....   | 30        |
| 2.3.2 Solubility of CRT.....  | 30        |
| 2.3.3 Characterization of CRT liposomes: particle size, polydispersity<br>index and encapsulation efficiency..... | 31        |
| 2.3.4 Characterization of CRT-CD inclusion complexes.....   | 33        |
| 2.3.5 IR spectrum of CRT- $\gamma$ -CD inclusion complex.....   | 35        |
| 2.3.6 DSC diagram of CRT- $\gamma$ -CD inclusion complex.....   | 37        |
| 2.4 Discussion.....   | 38        |
| 2.5 Conclusion.....   | 40        |
| <br>  |           |
| <b>CHAPTER 3 – Studies of Crocetin Formulations to Treat Alzheimer’s<br/>Disease.....</b>                         | <b>41</b> |
| 3.1 Introduction.....   | 41        |
| 3.2 Materials and methods.....  | 44        |
| 3.2.1 Materials.....  | 44        |
| 3.2.2 Cell culture.....   | 44        |
| 3.2.3 Animals.....  | 44        |
| 3.2.4 Experimental procedures.....  | 45        |
| 3.2.4.1 Cytotoxicity studies of CRT formulations.....   | 45        |
| 3.2.4.2 Western blot analysis.....  | 45        |
| 3.2.4.3 Determination of A $\beta$ <sub>1-40</sub> and A $\beta$ <sub>1-42</sub> levels by ELISA.....             | 46        |
| 3.2.4.4 Protective effect of CRT against H <sub>2</sub> O <sub>2</sub> -induced cell death.....                   | 47        |
| 3.2.4.5 Pharmacokinetics study of CRT.....  | 48        |

|  |           |
|--|-----------|
| 3.2.4.6 Bio-distribution study of CRT.....   | 49        |
| 3.2.4.7 Statistical analysis.....  | 49        |
| 3.3 Results.....   | 50        |
| 3.3.1 CRT formulations showed no toxicity toward neuronal cells and<br>Alzheimer’s disease model cells.....  | 50        |
| 3.3.2 Modulation of APP and CTFs expression.....   | 52        |
| 3.3.3 Modulation of A $\beta$ levels in 7PA2 cells by CRT.....   | 54        |
| 3.3.4 Protective effect of CRT against H <sub>2</sub> O <sub>2</sub> -induced cell death.....  | 56        |
| 3.3.5 Pharmacokinetics study of CRT.....   | 58        |
| 3.3.6 Bio-distribution study of CRT.....   | 61        |
| 3.4 Discussion.....  | 63        |
| 3.5 Conclusion.....  | 67        |
| <br>   |           |
| <b>CHAPTER 4 – Preparation and Characterization of CPP2 modified-<br/>Liposomal Formulations Loaded with Halofuginone and Artesunate for<br/>Targeted Colorectal Cancer Treatment.....</b> | <b>68</b> |
| 4.1 Introduction.....  | 68        |
| 4.1.1 Halofuginone and its applications in colorectal cancer therapy.....  | 68        |
| 4.1.2 Artesunate and its applications in colorectal cancer therapy.....  | 70        |
| 4.1.3 Cell-penetrating peptides for surface functionalization of liposomes<br>in cancer therapy.....   | 71        |
| 4.2 Materials and methods.....   | 74        |
| 4.2.1 Materials.....   | 74        |
| 4.2.2 Cell culture.....  | 74        |

|  |           |
|--|-----------|
| 4.2.3 Experimental procedures.....   | 74        |
| 4.2.3.1 Solubility of HF and ART.....  | 74        |
| 4.2.3.2 Synthesis of DSPE-PEG 2000-CPP2.....   | 75        |
| 4.2.3.3 Preparation of HF liposomes and ART liposomes.....   | 76        |
| 4.2.3.4 Characterization of liposomes: particle size, polydispersity<br>index and stability.....                                     | 77        |
| 4.2.3.5 Preparation of coumarin 6 liposomes for cellular uptake study  | 78        |
| 4.2.3.6 Cellular uptake study of CPP2-modified liposomes<br>(qualitative).....   | 79        |
| 4.2.3.7 Cellular uptake study of CPP2-modified liposomes<br>(quantitative).....  | 80        |
| 4.2.3.8 Statistical analysis.....  | 80        |
| 4.3 Results and discussion.....  | 80        |
| 4.3.1 Solubility of HF and ART.....  | 80        |
| 4.3.2 Synthesis of DSPE-PEG 2000-CPP2.....   | 81        |
| 4.3.3 Characterization of HF and ART liposomes: particle size,<br>polydispersity index and stability.....                            | 83        |
| 4.3.4 Cellular uptake study of CPP2-modified liposomes.....  | 87        |
| 4.4 Discussion.....  | 90        |
| 4.5 Conclusion.....  | 90        |
| <br>   |           |
| <b>CHAPTER 5–<i>In vitro</i> Study of Anticancer Activity of Halofuginone-<br/>Artesunate Formulations on Colon Cancer Cell.....</b> | <b>92</b> |
| 5.1 Introduction.....  | 92        |



|   |            |
|---|------------|
| 5.2 Materials and Methods.....  | 94         |
| 5.2.1 Materials.....  | 94         |
| 5.2.2 Cell culture.....   | 95         |
| 5.2.3 Experimental procedures.....  | 95         |
| 5.2.3.1 Cytotoxicity study of HF and ART formulations by MTT<br>assay.....                                | 95         |
| 5.2.3.2 Combination effect of HF and ART formulations to treat<br>colon cancer.....                       | 96         |
| 5.2.3.3 Statistical analysis.....   | 96         |
| 5.3 Results and discussion.....   | 96         |
| 5.3.1 Cytotoxicity study of HF and ART formulations by MTT assay.....                                     | 96         |
| 5.3.2 Combination effect of HF and ART formulations to treat colon<br>cancer.....                         | 100        |
| 5.4 Conclusion.....   | 106        |
| <b>CHAPTER 6–Conclusion and Future Perspective.....</b>   | <b>107</b> |
| 6.1 General conclusion.....   | 107        |
| 6.1.1 CRT formulations for Alzheimer’s disease treatment.....   | 107        |
| 6.1.2 Future perspective of CRT- $\gamma$ -CD inclusion complex for<br>Alzheimer’s disease treatment..... | 109        |
| 6.1.3 HF/ART formulations for colorectal cancer treatment.....  | 110        |
| 6.1.4 Future perspective of HF/ART liposomal formulations for<br>colorectal cancer treatment.....         | 112        |

|                              |            |
|------------------------------|------------|
| <b>REFERENCES.....</b>       | <b>114</b> |
| <b>PUBLICATIONS.....</b>     | <b>140</b> |
| <b>CURRICULUM VITAE.....</b> | <b>141</b> |